Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Ra Pharmaceuticals Inc (NASDAQ: RARX) acted responsibly on behalf of investors’ profitability in the planned sale to UBC SA.

On October 10, 2019, Ra Pharmaceuticals Inc (NASDAQ: RARX) and UBC SA announced that they had entered into a merger agreement. Under the terms of the deal Ra Pharma shareholders will receive $48.00 in cash for each Ra Pharma share at closing.  

Based in Cambridge, Massachusetts, and founded in 2008 Ra Pharmaceuticals Inc a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system.

The investigation is looking to uncover whether Ra Pharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $50.00 per share.

If you purchased Ra Pharmaceuticals Inc (NASDAQ: RARX) prior to October 10, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185